139 related articles for article (PubMed ID: 38601020)
21. Uveal Melanoma Cells Elicit Retinal Pericyte Phenotypical and Biochemical Changes in an in Vitro Model of Coculture.
Anfuso CD; Longo A; Distefano A; Amorini AM; Salmeri M; Zanghì G; Giallongo C; Giurdanella G; Lupo G
Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32756477
[TBL] [Abstract][Full Text] [Related]
22. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
[TBL] [Abstract][Full Text] [Related]
23. Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma.
Harda K; Szabo Z; Szabo E; Olah G; Fodor K; Szasz C; Mehes G; Schally AV; Halmos G
Molecules; 2018 Jun; 23(7):. PubMed ID: 29949880
[TBL] [Abstract][Full Text] [Related]
24. Pristimerin attenuates cell proliferation of uveal melanoma cells by inhibiting insulin-like growth factor-1 receptor and its downstream pathways.
Xie X; Xie S; Xie C; Fang Y; Li Z; Wang R; Jiang W
J Cell Mol Med; 2019 Nov; 23(11):7545-7553. PubMed ID: 31508890
[TBL] [Abstract][Full Text] [Related]
25. Modulation of AMPK Significantly Alters Uveal Melanoma Tumor Cell Viability.
Deliktas O; Gedik ME; Koc I; Gunaydin G; Kiratli H
Ophthalmic Res; 2023; 66(1):1230-1244. PubMed ID: 37647867
[TBL] [Abstract][Full Text] [Related]
26. Investigation of three new mouse mammary tumor cell lines as models for transforming growth factor (TGF)-beta and Neu pathway signaling studies: identification of a novel model for TGF-beta-induced epithelial-to-mesenchymal transition.
Lenferink AE; Magoon J; Cantin C; O'Connor-McCourt MD
Breast Cancer Res; 2004; 6(5):R514-30. PubMed ID: 15318933
[TBL] [Abstract][Full Text] [Related]
27. ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells.
Kaochar S; Dong J; Torres M; Rajapakshe K; Nikolos F; Davis CM; Ehli EA; Coarfa C; Mitsiades N; Poulaki V
Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):132-143. PubMed ID: 29332125
[TBL] [Abstract][Full Text] [Related]
28. BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors.
Han A; Purwin TJ; Bechtel N; Liao C; Chua V; Seifert E; Sato T; Schug ZT; Speicher DW; Harbour JW; Aplin AE
Oncogene; 2021 Jan; 40(3):618-632. PubMed ID: 33208912
[TBL] [Abstract][Full Text] [Related]
29. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma
Zhou J; Jin B; Jin Y; Liu Y; Pan J
Theranostics; 2017; 7(6):1447-1462. PubMed ID: 28529629
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
Hofmann UB; Kauczok-Vetter CS; Houben R; Becker JC
Clin Cancer Res; 2009 Jan; 15(1):324-9. PubMed ID: 19118061
[TBL] [Abstract][Full Text] [Related]
31. Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro.
Brown KA; Aakre ME; Gorska AE; Price JO; Eltom SE; Pietenpol JA; Moses HL
Breast Cancer Res; 2004; 6(3):R215-31. PubMed ID: 15084245
[TBL] [Abstract][Full Text] [Related]
32. Effects of Long-term Serial Passaging on the Characteristics and Properties of Cell Lines Derived From Uveal Melanoma Primary Tumors.
Mouriaux F; Zaniolo K; Bergeron MA; Weidmann C; De La Fouchardière A; Fournier F; Droit A; Morcos MW; Landreville S; Guérin SL
Invest Ophthalmol Vis Sci; 2016 Oct; 57(13):5288-5301. PubMed ID: 27723895
[TBL] [Abstract][Full Text] [Related]
33. Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071.
Piperno-Neumann S; Larkin J; Carvajal RD; Luke JJ; Schwartz GK; Hodi FS; Sablin MP; Shoushtari AN; Szpakowski S; Chowdhury NR; Brannon AR; Ramkumar T; de Koning L; Derti A; Emery C; Yerramilli-Rao P; Kapiteijn E
Mol Cancer Ther; 2020 Apr; 19(4):1031-1039. PubMed ID: 32029634
[TBL] [Abstract][Full Text] [Related]
34. Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152).
Oláh G; Dobos N; Vámosi G; Szabó Z; Sipos É; Fodor K; Harda K; Schally AV; Halmos G
Eur J Pharm Sci; 2018 Oct; 123():371-376. PubMed ID: 30076951
[TBL] [Abstract][Full Text] [Related]
35. CD166high Uveal Melanoma Cells Represent a Subpopulation With Enhanced Migratory Capacity.
Djirackor L; Kalirai H; Coupland SE; Petrovski G
Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2696-2704. PubMed ID: 31242292
[TBL] [Abstract][Full Text] [Related]
36. Characterization of Uveal Melanoma Cell Lines and Primary Tumor Samples in 3D Culture.
Aughton K; Shahidipour H; Djirackor L; Coupland SE; Kalirai H
Transl Vis Sci Technol; 2020 Jun; 9(7):39. PubMed ID: 32832244
[TBL] [Abstract][Full Text] [Related]
37. The AMP-dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma.
Chua V; Han A; Bechtel N; Purwin TJ; Hunter E; Liao C; Harbour JW; Aplin AE
Pigment Cell Melanoma Res; 2022 Jan; 35(1):78-87. PubMed ID: 34347929
[TBL] [Abstract][Full Text] [Related]
38. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
[TBL] [Abstract][Full Text] [Related]
39. Autocrine impact of VEGF-A on uveal melanoma cells.
Koch KR; Refaian N; Hos D; Schlereth SL; Bosch JJ; Cursiefen C; Heindl LM
Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2697-704. PubMed ID: 24677103
[TBL] [Abstract][Full Text] [Related]
40. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
Ambrosini G; Sawle AD; Musi E; Schwartz GK
Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
